Hypericin – Autoimmune Diseases

Inflammatory Bowel Diseases (IBD): Hy BioPharma aims to bring to market an oral formulation. Additionally, the company is pursuing a novel, controlled-release, site-directed formulation for Hypericin.

Psoriasis: For mild-to-moderate cases, Hy BioPharma is developing a topical gel formulation for photodynamic therapy. For severe cases, Hypericin administered orally will be evaluated clinically as a systemic treatment.

Inflammatory Bowel Diseases (IBD)
Ulcerative colitis and Crohn's disease, known collectively as inflammatory bowel diseases (IBD), currently affect 0.5-1% of the Western world population. Over one million are affected in the United States (525,000 ulcerative colitis, 490,000 Crohn's disease) and four million worldwide. Ulcerative colitis is restricted to the colon and primarily affects the mucosa while Crohn's disease can affect all regions of the gastrointestinal tract.

Psoriasis
Psoriasis is an autoimmune skin disease in which T-lymphocytes play a major role.

Psoriasis affects about 18 million people worldwide, with more than 7.6 million adults diagnosed with the disease in the United States. Of these, about 30% or 2.3 million have moderate to severe psoriasis, affecting the patient’s daily lifestyle. Every year, about 200,000 new cases of psoriasis are diagnosed.